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Letter: rationalising aminosalicylates in inflammatory bowel 
disease—authors' reply
We thank Dr Nicolaides and colleagues for their interest in our 
review article.1,2 We agree that emerging data support the safe 
withdrawal of 5-aminosalicylates (5-ASA) in patients escalated to 
immunomodulators. A very recent retrospective analysis of patients 
with ulcerative colitis (UC) receiving 5-ASA who commenced either 
thiopurine or methotrexate provides further important data.3 In 
this study of 4068 patients identified from a national administrative 
claims database in the United States, there was no apparent benefit 
to continuation of 5-ASA over 2.5 years after starting immunomodu-
lator, with no reduction in risk of UC-related hospitalisation, surgery, 
relapse requiring corticosteroids or escalation to biologic therapy.
Further, data from the SECURE-IBD registry has called into ques-
tion the safety of 5-ASA and sulfasalazine in the current COVID-19 
pandemic.4 Of 525 cases of polymerase chain reaction-confirmed 
COVID-19 in both paediatric and adult patients with IBD, of which just 
under one-third required hospitalisation, 117 were receiving 5-ASA or 
sulfasalazine. Surprisingly, on multivariable regression analysis, use of 
5-ASA/sulfasalazine was associated with increased risk of the primary 
outcome of severe COVID-19, defined as a composite of intensive care 
admission, ventilation and/or death, with adjusted odds ratio of 3.14 
(95% CI 1.28-7.71, P = 0.01). In a direct comparison, this group also had 
worse outcomes from COVID-19 than those treated with anti-tumour 
necrosis factor therapy. Although unmeasured confounding factors 
cannot be excluded, it is notable that the multivariable regression anal-
ysis adjusted for multiple known risk factors for more severe COVID-
19 disease course including age, gender, smoking status, comorbidities 
and use of systemic corticosteroids.5,6 Adjustment was also made for 
inflammatory bowel disease diagnosis (Crohn's disease or UC/IBD 
unspecified) and for severity. While ethnicity was not adjusted for, 
84.2% of patients were Caucasian. Although this apparent association 
between 5-ASA and worse COVID-19 outcome requires replication 
and ideally confirmation by identification of any underlying biological 
mechanism, these data potentially provide further rationale to with-
draw 5-ASA therapy where possible.
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